MRI has made significant contribution to medical diagnosis because it provides in vivo information non-invasively and without ionizing radiation.To this end,19F MRI is especially attractive because there is no in vivo 19F signal as background and its signal can be both qualified and quantified.So,19F MRI has the potential to become a valuable tool for imaging-guided drug therapy (personalized medicine).However,the development of 19F MRI falls far behind of its cousin,1H MRI,due to lacking of suitable imaging agent for over 40 years.Herein,we report a class of perfluoro-tert-butanol derivatives as efficient 19F MRI agents.These imaging agents solved the long standing problems with 19F MRI,such as signal splitting,low signal intensity,low in vivo stability,complex formulation procedures,and,most important of all,excessive internal organ retention.With such stable and rapidly excreted 19F MRI agents,19F MRI will play a more important role in quantitative diagnosis,drug delivery and tracing,personalized medicine,and beyond.